Generic Synera Availability
Last updated on Jun 11, 2025.
Synera is a brand name of lidocaine/tetracaine topical, approved by the FDA in the following formulation(s):
SYNERA (lidocaine; tetracaine - patch;topical)
-
Manufacturer: GALEN SPECIALTY
Approval date: June 23, 2005
Strength(s): 70MG;70MG (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Synera. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
More about Synera (lidocaine / tetracaine topical)
- Synera consumer information
- Check interactions
- Compare alternatives
- Reviews (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: topical anesthetics
- En español
Related treatment guides
Related/similar drugs
Lidocaine Viscous
Lidocaine Viscous is used for anesthesia, gastrointestinal surgery, gastrointestinal tract ...
Lidoderm
Lidoderm is a lidocaine patch used to relieve nerve pain after shingles by numbing the skin and ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Ropivacaine
Ropivacaine is used for cesarean section, labor pain, local anesthesia
Tetracaine topical
Tetracaine topical is used for allergic urticaria, cold sores, local anesthesia, skin rash, urticaria
Bupivacaine
Bupivacaine is used for cesarean section, local anesthesia, postoperative pain
Lidocaine ophthalmic
Lidocaine ophthalmic is used for local anesthesia, ophthalmic surgery
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.